Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg

World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned dermatologists Dr. Rodney Sinclair and Dr. David Goldberg have joined its ABS-201 Scientific Advisory Board. They will guide the scientifi ...